Regeneron Announces Presentation at the Bank of America Merrill Lynch 2011 Health Care Conference

May 2, 2011

TARRYTOWN, N.Y., May 2, 2011 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the Bank of America Merrill Lynch 2011 Health Care Conference on Tuesday, May 10, 2011 at 9:20 a.m. Pacific Time (12:20 p.m. Eastern Time). The session may be accessed through the Company’s web site, www.regeneron.com, on the Investor Relations page. An archived version of the presentation will be available after the live webcast through May 27, 2011.

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration, central retinal vein occlusion, and diabetic macular edema), and certain cancers. Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer. Additional information about Regeneron and recent news releases are available on Regeneron’s web site at www.regeneron.com.

    Contact Information:

    Michael Aberman, M.D.                     Peter Dworkin
    Investor Relations                        Corporate Communications
    914.345.7799                              914.345.7640
    michael.aberman@regeneron.com             peter.dworkin@regeneron.com

SOURCE Regeneron Pharmaceuticals, Inc.

Source: newswire

comments powered by Disqus